We performed analysis of the distribution of dysplasia within BE using pretreatment biopsy data from two randomized controlled trials (RCTs) of radiofrequency ablation for dysplastic BE: the SURF (Surveillance vs. Radiofrequency Ablation) trial and the AIM Dysplasia (Ablation of Intestinal Metaplasia (AIM) Containing Dysplasia) trial. We used generalized linear models with generalized estimating equations (GEE) to estimate prevalence differences for dysplasia depending on the standardized location of biopsies. We performed Monte Carlo simulation of biopsy regimens to estimate their yield for any dysplasia within segments.
INTRODUCTION
Barrett's esophagus (BE) is a common, premalignant change of the normal squamous epithelium of the esophagus to a salmoncolored columnar mucosa with goblet cells (1) (2) (3) . Th e risk of malignant transformation to esophageal adenocarcinoma varies greatly, with the most important determinant being histologic grade ( 4, 5 ) . Th e diagnosis of dysplasia within a Barrett's segment greatly increases the rate of progression to cancer ( 6, 7 ) . Because severity of dysplasia decides subsequent treatment, detection of dysplasia within a BE segment is the most important aspect of chronic care in BE, and is the purpose of surveillance endoscopy programs ( 8 ) .
Although currently recommended biopsy regimens, such as the Seattle protocol of four-quadrant biopsies every 1-2 cm ( 1 ), have the virtue of simplicity, no data regarding the distribution of dysplasia drive these recommendations. Instead, this protocol is designed to get a representative random sample of mucosa. Better characterization of the spatial distribution of dysplasia might produce biopsy regimens with decreased total numbers of biopsies and increased yield of dysplasia per biopsy. Such regimens might also decrease false negative results and, if they imply fewer overall biopsies, also decrease costs associated with histology, postprocedure pain, and any biopsy complications. Th e development of a regimen the sampling density of which approximates the observed distribution of dysplasia across a wide range of segment lengths would improve current practices by drawing biopsies from the areas most likely to yield dysplasia. Using biopsy data from two recent, methodologically rigorous randomized controlled treatment trials of BE, we sought to describe the proximal to distal distribution of dysplasia in treatment-naive BE, and to simulate the yield of dysplasia of various hypothetical biopsy regimens for BE surveillance.
METHODS

Data sources
We performed an analysis of the distribution of dysplasia longitudinally within the BE segment using pretreatment biopsy data from two randomized controlled trials (RCTs) of radiofrequency ablation for dysplastic BE. Each trial was examined in isolation and in pooled analyses. Th ese trials were as follows.
(i) Th e Surveillance vs. Radiofrequency Ablation (SURF) trial .
Th e SURF trial ( 9 ) was conducted at nine European BE treatment centers. Eligible patients underwent endoscopy demonstrating BE with low-grade dysplasia within 18 months before enrollment. An expert central pathology panel confi rmed community-based diagnoses of low-grade dysplasia. Patients were excluded for prior endoscopic treatment for BE, history of high-grade dysplasia or adenocarcinoma, active secondary malignancy, estimated life expectancy of <2 years (according to the enrolling physician), and age of ≤18 or ≥85 years.
All patients required a baseline qualifying endoscopy within 6 months before randomization to exclude visible abnormalities, high-grade dysplasia, or adenocarcinoma. Baseline qualifying endoscopies were performed using high-resolution endoscopy with biopsies obtained according to the modifi ed Seattle protocol (4-quadrant biopsies/2-cm intervals) with additional biopsy and documentation of any visible abnormalities or raised lesions. Patients were subsequently randomized to either treatment or surveillance ( 9 ) . Data from the baseline qualifying exam were used in the present study.
(ii) Th e Ablation of Intestinal Metaplasia (AIM) Containing Dysplasia trial . Th e AIM Dysplasia trial ( 7 ) was conducted at 19 US sites. Eligible patients were between 18 and 80 years of age and had endoscopically evident, nonnodular, dysplastic BE of no more than 8 cm in length. Patients with prior endoscopic mucosal resection (EMR) and complete clearance of nodularity at least 8 weeks before enrollment were allowed. Exclusion criteria were pregnancy, active esophagitis or stricture precluding passage of the endoscope, a history of esophageal cancer, esophageal varices, uncontrolled coagulopathy, or a life expectancy of <2 years, as judged by the site investigator.
A central pathology lab confi rmed diagnoses of dysplasia. Baseline visits were performed by either the referring gastroenterologist or at participating study sites. Endoscopic biopsies were performed with maximum-capacity or jumbo forceps in four quadrants every 1-2 cm throughout the original length of BE; in addition, directed biopsies were performed at sites with any visible abnormalities ( 7 ) .
Statistical methods
For the purposes of analyses in this study, only pathology samples from baseline endoscopies were included. Patients with less than two biopsy levels were excluded, because such instances provided no information regarding proximal-to-distal distribution. Th e proximal-to-distal location of biopsy levels was standardized to the maximum distance of the BE segment from the top of gastric folds (TGF). For example, a biopsy level at TGF would be assigned a location of 0, a biopsy level 8 cm proximal to TGF within an 8 cm segment of BE would be assigned a location of 1, and a biopsy level 2 cm proximal to TGF in an 8 cm segment would be assigned a location of 0.25. In this way, spatial distributions of dysplasia within BE segments of varying lengths could be standardized to allow assessment of proximal-to-distal distribution, regardless of length of BE.
We examined the probability of any biopsy within a given biopsy level containing dysplasia using generalized estimating equations (GEE) with an auto-regressive correlation matrix, examining random eff ects of the two trials and controlling for repeated measures within a patient. GEE can be used to estimate correct confi dence intervals and P values in the setting of multiple observations for each individual. With an auto-regressive correlation matrix, this approach also allowed us to account for the possibility that areas of dysplasia are "lumped together, " i.e., that having one biopsy at a given level positive for dysplasia increased the probability that a subsequent biopsy from that or nearby levels would also be positive.
We used generalized linear models to estimate prevalence and prevalence diff erences for dysplasia depending on the standardized location of biopsy levels. We queried for a nonlinear relationship between the yield for dysplastic biopsies and location by fi tting and statistically comparing nested models with an ordinary linear specifi cation of the eff ect of location, with quadratic and cubic parameterizations, and with natural log and exponential transformations. To examine whether the prevalence diff erence between standardized biopsy location and the yield for dysplasia was modifi ed by clinical or endoscopic features, we compared nested models with and without hierarchically specifi ed interaction terms using QIC (quasi-likelihood under the independence model criterion), a model-fi t statistic to compare the fi t of models estimated with GEE ( 10 ) . To estimate the potential for bias because of any missing location data, we performed multiple imputation sensitivity analyses among patients with missing location data with prevalence ratios for dysplasia of 1 to 4 in the opposite direction of the observed association. In order to examine the possibility that distal biopsies in segments <4 cm may have inadvertently sampled the gastric cardia, we performed sensitivity analysis limited to patients with >4 cm Prague M length. In addition, we examined the eff ect of excluding the distal-most observation in each patient. To examine the possibility that prior EMR perturbed the natural distribution of dysplasia at baseline in these trials, we also performed analysis excluding patients with prior EMR.
Simulation methods
A simulation study was performed to examine the hypothetical yield of biopsy regimens refl ecting the observed spatial distribution of dysplasia. Pooled subjects' baseline qualifying endoscopies from both trials with dysplasia in at least one biopsy fragment were included. In contrast to the model for the prior outcome, which estimated the probability of fi nding any dysplasia within any sample at a given level, the model for simulation predicted the likelihood of fi nding dysplasia in a single fragment in the entirety of the biopsy run. Th is best refl ects current management of these patients, as the worst dysplasia fi nding in any single fragment dictates the patient's care. In addition to the best fi tting quadratic parameterization, this model included a hierarchically specifi ed interaction term with segment length. GEE were specifi ed similarly to the primary analysis.
Monte Carlo sampling of simulated biopsy fragments was stratifi ed by segment length and 1 or 2 cm increments of location, depending on the regimen being simulated. Samples for 2 cm regimens were evenly split between the top and bottom 1 cm halves. Each sample was taken from a Bernoulli distribution (that is used for "yes or no" probabilities) of the absolute prevalence risk of dysplasia, informed by the location and segment length of the model for simulation. If one or more samples from a simulated patient yielded dysplasia, the sampling regimen was considered to be sensitive for detecting dysplasia. For segments of 1 cm in length, it was assumed that one half of the recommended biopsies from the q2cm (every 2 cm) regimen would be taken. We reported the mean for sensitivity as a function of segment length, increasing the number of Monte Carlo samples until simulation standard error was negligible. In analyses of distribution of dysplasia, dysplasia found in targeted biopsies was included in addition to that found in random biopsies, whereas in simulations of hypothetical random biopsy protocols, only dysplasia found on random biopsy was included.
RESULTS
Of 140 patients in the SURF study and 127 patients in the AIM Dysplasia trial, 115 and 77 respectively had fragment-level information regarding the location and histologic grade of all biopsy fragments at the baseline endoscopy complete and detailed enough to allow the analyses described above ( Figure 1 ). Of these 93 and 64, respectively, had at least two biopsy levels, yielding 157 patients for the pooled spatial analysis. Patients in both trials were predominantly male, Caucasian, and older. Th e mean Prague M length in the SURF study was 5.6 cm, and the mean in the AIM Dysplasia trial, which was limited to patients with no more than 8 cm of BE, was 4.4 cm ( Table 1 ). In the AIM Dysplasia trial, 50 of 127 (39%) patients had incomplete data for histology locations at baseline; in the SURF study, 25 of 140 (18%) patients had incomplete data; in pooled analysis, 75 of 267 (28%) patients had incomplete data.
Independent analysis of each trial yielded a statistically signifi cant, positive linear association between more proximal location of biopsy level within the BE segment and the fi nding of dysplasia among any of the fragments at that level ( Table 2 ). Overall, biopsies from the proximal-most quarter of the BE segment were almost twice as likely to demonstrate dysplasia as those from the most distal quarter (46.6% ). In the SURF trial, compared with biopsy levels in the distal-most quarter segment, biopsy levels in the proximal-most quarter segment had an absolute 12.9% (95% CL: 1.0-24.8%) higher prevalence of dysplasia. Th e second-most proximal segment had a prevalence diff erence of 16.8% (95% CL: 2.5-31.0%) and the second-most distal segment had a prevalence diff erence of 11.6% (95% CL: 0.0-24.5%). Th ese fi ndings were insensitive to exclusion of targeted biopsies. Th e absolute prevalence of dysplasia was higher in the AIM Dysplasia trial but followed a similar pattern to the SURF trial.
In the pooled trials, compared with biopsy levels in the distalmost quarter segment, biopsy levels in the proximal-most quarter segment had an absolute 22.6% (95% CL: 12.8-32.5%) higher prevalence of dysplasia. Th e second-most proximal segment had a prevalence diff erence of 23.1% (95% CL: 12.1-34.1%) and the second-most distal segment had a prevalence diff erence of 15.3% (95% CL: 5.1-24.5%).
Th e best-fi tting nonlinear parameterization based on QIC was the quadratic fi t ( Figure 2 ), a signifi cantly better fi t than the simple linear parameterization (quasi-likelihood ratio statistic=5.56, P =0.018). Th e prevalence of dysplasia in individual biopsy fragments, rather than biopsy levels, followed a similar distribution ( Figure 3 ). Multiple imputation analysis for missing data found that a risk ratio of >2 in the opposite direction of that observed among patients with missing samples would be required to reverse the direction of eff ect. Th e eff ect remained statistically signifi cant in 99% of random normal imputations of missing biopsy levels.
Th e relationship between proximal-to-distal location and the prevalence of dysplasia was largely insensitive to baseline clinical and endoscopic characteristics. However, there was statistically signifi cant modifi cation of the prevalence diff erence at an α threshold of 0.05 by age, where younger patients had a greater proximal predisposition of dysplasia and older patients had a weaker predisposition. Th ere were insignifi cant modifi cations of the prevalence diff erence for BMI ( P =0.098), where patients with higher BMI had a stronger proximal predisposition, and for Prague C length ( P =0.105), where patients with longer Prague C length had a weaker proximal predisposition. No other potential modifi ers of the risk diff erence approached statistical signifi cance.
Sensitivity analyses suggest that the spatial distribution of dysplasia was insensitive to segment length or the inclusion of patients with prior EMR. Limitation of the analysis to BE segments over 4 cm had no signifi cant eff ect on the risk diff erence from TGF to the top of intestinal metaplasia from 24.9% (95% CL: 14.0-35.8%) to 24.3% (95% CL: 7.4-41.3%). Excluding the distal-most sample from each patient attenuated the eff ect, but it remained statistically signifi cant at 20.0% (95% CL: 0.6-40.0%). Excluding the 11 patients with prior EMR also had no signifi cant eff ect, yielding a risk diff erence of 26.1% (95% CL: 14.8-37.4%).
Monte Carlo simulation of biopsy fragments among patients with dysplasia at the baseline endoscopy suggested that the Cotton et al.
endoscopic characteristics, but was signifi cantly increased among younger patients. We also present simulation studies that suggest that proximal oversampling could allow better sensitivity in those with shorter segments of BE, and for fewer biopsies in patients with longer segment BE. Simulations suggest such regimens could increase the sensitivity for dysplasia among patients with shortsegment BE by >30% and decrease the number of biopsies among sensitivity of biopsy regimens varied widely depending on segment length. Among patients with shorter segments, random draws of biopsy fragments oft en failed to identity any dysplasia ( Figure 4 ). Sensitivity decreases of >30% were observed at segment lengths ≤3 cm by random error in biopsy fragment selection. Simulations of biopsy regimens with increased proximal samples suggested that such regimens would perform better than a uniform regimen. Th e best overall regimen was a "q1cm: 8, 8, 2, 2…" regimen in which 8 biopsies were taken at the proximal-most 1 cm level, 8 biopsies at the next 1 cm level, and 2 biopsies in each subsequent, more distal 1 cm level. Th is regimen decreased the number of biopsies in longer segments of BE, but increased the number of biopsies in shorter segments. Interestingly, the worst performing regimen we modeled was four-quadrant biopsies every 2 cm that was projected to miss at least one in fi ve patients with dysplasia who had a segment length of the BE of <4 cm. In contrast, a highly accurate q2cm regimen could be constructed, but only with marked oversampling of the proximal BE (12 biopsies over 2 cm; Figure 4 ). Figure 5 demonstrates the total number of biopsies necessary to complete each modeled regimen as a function of BE segment length. Although short segments of BE require higher numbers of biopsies in the proposed weighted regimens, longer segments of disease actually result in fewer biopsies, despite achieving sensitivities equal to or better than standard regimens.
DISCUSSION
In a post hoc analysis of two RCTs, we found a signifi cantly increased prevalence of dysplasia proximally within a fi eld of BE. Th is relationship was stable over most baseline clinical and . Simulated yield for dysplasia within any sample for a given patient under selected classical and novel biopsy regimens by segment length. Biopsy regimens missed dysplasia in simulations of shorter segments because of less total biopsies introducing the possibility of missing a single dysplastic biopsy fragment at random. All regimens performed well among longer segments. Note that q2cm (every 2 cm) regimens' sensitivity tended to drop slightly at even-numbered segment lengths because the same number of biopsies was performed over a larger area compared with a segment 1 cm shorter. . Simulated number of biopsies under selected classical and novel biopsy regimens by segment length. In short segments the proposed biopsy regimens require more biopsies than uniform regimens, whereas at longer segment lengths they require more than uniform q2cm (every 2 cm) biopsies but less than q1cm (every 1 cm).
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patients with long-segment BE of >6 to 9 cm without compromising sensitivity.
BE management depends on accurate risk stratifi cation. Surveillance endoscopy taking both random and targeted biopsies of any mucosal abnormalities throughout the BE segment is the standard of care (11) (12) (13) . Most patients with BE have nondysplastic disease ( 14, 15 ) . Both the AIM Dysplasia and SURF trials demonstrated a benefi t of ablative therapy in patients with low-grade dysplasia and high-grade dysplasia ( 7, 9 ) . As such, the identifi cation of dysplasia in a patient with BE is vital, as it is the deciding factor in treatment decisions for BE. Optimization of sampling techniques has the potential to benefi t a large population of patients.
Given that the distribution of dysplasia at baseline endoscopies in these two trials is not linear or uniform, biopsy regimens that would perfectly refl ect this distribution would be complicated. Much of the burden of surveillance of nondysplastic BE falls to community gastroenterologists or surgeons who may not specialize in esophageal disease. As such, widespread adoption of novel biopsy regimens will be facilitated if they are memorable and simple to implement. Th e best performing simple regimen in simulation studies was the q1cm (every 1 cm): "8, 8, 2, 2…" regimen that requires 8 biopsies in the proximal-most 1 cm level and 8 biopsies at the second most proximal 1 cm level, with 2 biopsies at each more distal 1 cm level. Th is regimen has the advantages of ease of recall for the endoscopist, increase in the sensitivity in shorter-segment BE, and decrease in the number of biopsies in long-segment BE. A q2cm regimen (q2cm: "12, 12, 2…") had a similar distribution of biopsies and performed almost as well.
Our fi ndings are novel, but are generally consistent with prior studies regarding the yield of biopsies in BE surveillance. Previous work suggests that when utilizing the Seattle protocol, q1cm four-quadrant biopsies detect more dysplasia than q2cm regimens, a fi nding replicated in our simulation ( 16 ) . A subsequent study countered this fi nding, but had a small sample size and could only detect a very large diff erence in yield between the q1cm and q2cm regimens tested ( 17 ) . A larger study found a very large increase in detection with systematic rather than random biopsies ( 18 ) . Early studies of dysplasia in esophagectomy specimens and a study of early neoplasia did not fi nd a spatial predisposition, but given their sample sizes, had limited power to detect eff ects of the magnitude we report (19) (20) (21) (22) (23) . Th ese studies suggested that areas of highgrade dysplasia were generally contiguous but could vary greatly in location and extent.
In distinction to our fi ndings, a study set in Germany found a strong predisposition of esophageal and junctional adenocarcinoma (T1-T3) to the distal third of Barrett's segments, but this was aft er neoadjuvant chemotherapy and esophagectomy ( 24 ) . Th ese fi ndings may refl ect a substantively diff erent population, a more advanced stage of disease, or a setting in an era before ablative therapies were the standard of care for dysplastic BE. Esophageal adenocarcinoma is generally more common in the distal third of the esophagus ( 25, 26 ) . Because Barrett's carcinogenesis is a multistep process over time, the exposures and events that cause progression from nondysplastic to dysplastic BE may, on average, have a diff erent spatial distribution in the esophagus than the exposures and events that cause progression of dysplasia to early cancer.
Th e proximal predisposition of dysplasia seems counterintuitive. Most other manifestations of refl ux disease worsen with increasing acid exposure. For instance, although the degree of proximal extension of the refl uxate is associated with severity of erosive disease, it is clear the distal esophagus is exposed to refl uxate more oft en, and for longer periods of time, than more proximal areas (27) (28) (29) . Th erefore, it would seem most logical for the distal BE to preferentially harbor dysplasia-the exact opposite of what we actually observed. What might explain our fi ndings? Several possibilities exist. As the acidity of the refl uxate decreases as it extends proximally, the observed pattern would make sense if weakly acidic/neutral refl uxate promoted dysplasia within BE more so than strongly acidic refl uxate, or if there was a protective eff ect of strongly acidic refl uxate in BE ( 30 ) . Th is pattern might also be consistent with a selection process that favors increased proliferation of a dysplastic clone into more proximal areas ( 31, 32 ) . Perhaps the multilayered epithelium at the new squamocolumnar junction is especially prone to transformation and is a fertile area for the development of dysplasia ( 33, 34 ) . Although these or other mechanisms could underlie the observed distribution of dysplasia in this study, inference as to the pathogenesis explaining these fi ndings is not possible from the present data.
Th is study has several limitations. Because the AIM Dysplasia protocol did not mandate sampling of the cardia, we have restricted our analyses and recommendations to the tubular esophagus. In addition, a minority of patients had missing location data in each study, but multiple imputation analysis found the potential for bias to be small unless missing data were strongly biased in the opposite direction of our observed eff ect, which is unlikely. Next, although we examined eff ect measure modifi cation, statistical power to detect modifi cation of eff ects is generally much less than to detect the eff ect itself. It is relatively unlikely that we would detect subtle eff ect measure modifi ers in a study of this size. In addition, insuffi cient data prevented us from examining whether a diff erential eff ect existed for high-grade compared with low-grade dysplasia. Simulation studies such as those performed here are limited in that random draws of biopsies or biopsy levels may fail to approximate the actual clinical process of biopsy selection, as each additional hypothetical biopsy is presumed to have the same yield as the actual biopsies taken at that level. Our study determined only the longitudinal, not circumferential, predisposition to dysplasia. Studies suggest that, at least in the case of early adenocarcinoma or high-grade dysplasia, there may additionally be a circumferential clustering of disease ( 35, 36 ) . Furthermore, this is a single analysis and, despite being performed on two, high-quality, multicenter, randomized clinical trials, should be replicated in further observational or randomized studies.
Th ese results are likely generalizable to populations that include patients with BE with dysplasia under similar conditions to the study population regardless of the underlying prevalence of dysplasia, given that the biological factors underlying dysplasia distribution would not be expected to be aff ected by dysplasia prevalence. However, diff erences in the performance of EGD or the quality of ✓ The addition of biopsies not targeted to visible lesions improves the sensitivity of biopsy regimens over targeted biopsies alone, and systematic biopsy regimens outperform unstructured regimens.
WHAT IS NEW HERE
✓ Dysplasia is more common in the proximal than distal regions of Barrett's segments. Biopsy regimens that oversample the proximal Barrett's segment perform better than uniform regimens in simulations. In short-segment BE, prevalent dysplasia is frequently missed because of a small number of samples and random error.
the histological grading of dysplasia have the potential to change both the test characteristics of surveillance endoscopy, and, potentially, the fi ndings we report here. Th erefore, inference from this study is most reliable in cases of dysplasia as diagnosed by an endoscopist with expertise in managing BE in concert with a dedicated gastrointestinal pathologist. A further limitation of sampling from referral populations such as these is the possibility of selection bias. It is possible that the distribution of dysplasia in patients referred to such centers does not refl ect that in general populations. However, community-based studies may also have serious threats to internal validity because of missing data for biopsy location and the possibility nonsystematic sampling regimens.
Th e study also has several strengths. Because the same spatial predisposition of dysplasia is observed independently in these two multicenter, RCTs, our fi ndings are likely robust to both random variation and idiosyncratic eff ects of individual centers. In contrast to many observational data sets, patients selected for these trials were known to be treatment naive, were subject to carefully recorded systematic biopsy, and had rigorous review of their histologic grade.
In summary, we report the results of pooled analysis of two multicenter, RCTs that independently support a proximal predisposition of dysplasia within Barrett's segments with dysplasia. We also propose a "q1cm: 8, 8, 2, 2…" biopsy regimen and an alternative "q2cm: 12, 12, 2…" regimen that both take advantage of the observed distribution of dysplasia and allow for a decreased number of biopsies in patients with longer segments of BE compared with a q1cm four-quadrant regimen. Th ese simulations also demonstrate that in shorter segments, even with weighted sampling regimens, dysplasia detection was very sensitive to sample number. Even small decrements in the number of samples taken were refl ected in diminished sensitivity of the regimens. Given that poor adherence to rigorous sampling regimens has been described, this fi nding speaks to the need for novel mucosal sampling technologies ( 37 ) . Such a regimen would complement, but not replace, careful examination of the Barrett's segment with targeted biopsy of mucosal abnormalities. If these results can be replicated in further studies, this change in practice has the potential to improve risk stratifi cation of patients with BE without requiring additional time or expense.
